Clinical Trials Logo

Chronic Hepatitis B clinical trials

View clinical trials related to Chronic Hepatitis B.

Filter by:

NCT ID: NCT02883647 Recruiting - Chronic Hepatitis b Clinical Trials

Therapeutic Effects and Long-term Follow-up After Ending Nucleos(t)Ide Analogs Therapy in Chronic Hepatitis b

Start date: January 2014
Phase: N/A
Study type: Observational

The study is to observe the therapeutic effects and long-term follow-up after ending anti-HBV therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.

NCT ID: NCT02863757 Recruiting - Chronic Hepatitis B Clinical Trials

Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease

Start date: August 2016
Phase:
Study type: Observational

The purpose of this study is to determine the disease progression in CHB/NAFLD compared with CHB and NAFLD including liver cirrhosis, cirrhotic complications and hepatocellular carcinoma (HCC).

NCT ID: NCT02838810 Recruiting - Chronic Hepatitis B Clinical Trials

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Start date: June 2016
Phase: Phase 4
Study type: Interventional

As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.

NCT ID: NCT02822547 Recruiting - Chronic Hepatitis B Clinical Trials

Study on Treatment of Pegylated Interferon Alfa 2a(Pegasys®) in the Korean Chronic Hepatitis B(CHB) Adults

Start date: March 2015
Phase: Phase 4
Study type: Interventional

Patients will receive Peginterferon alfa-2a according to the standard medical practice but the observation period is 12 weeks

NCT ID: NCT02817685 Recruiting - Chronic Hepatitis B Clinical Trials

Follow-up Strategy of Chronic Hepatitis B for Early Detection and Diagnosis of Hepatocellular Carcinoma: A Randomized Control Trial

Start date: May 2016
Phase: N/A
Study type: Observational

This study is a randomized control prospective study. The aim of this study is to establish an all-round and convenient follow-up strategy of Chronic Hepatitis B for early detection and diagnosis of Hepatocellular Carcinoma (HCC), by investigating whether different surveillance time intervals and surveillance methods are beneficial for chronic hepatitis B and cirrhotic patients with different risk of HCC.

NCT ID: NCT02805738 Recruiting - Chronic Hepatitis B Clinical Trials

Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet

Start date: April 2016
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet

NCT ID: NCT02745704 Recruiting - Chronic Hepatitis B Clinical Trials

The Optimizing Treatment of PegIFN Alfa in HBeAg-negative CHB Patients With Low Level HBsAg

Start date: April 2016
Phase: Phase 4
Study type: Interventional

As HBsAg clearance is uncommon in chronic hepatitis B (CHB) patients on nucleoside analogues (NAs) therapy. The purpose of this study is to optimize HBsAg clearance in CHB Patients with sequential treatment of pegylated interferon alpha and NAs.

NCT ID: NCT02581033 Recruiting - Clinical trials for Chronic Hepatitis B.

Determinants of Virological Response After Discontinuation of Nucleoside Analogue Therapy in Hepatitis B Patients

STOP
Start date: May 2014
Phase: N/A
Study type: Interventional

Evaluation of the rate of sustained virological response among HBeAg-negativechronic hepatitis B patients who discontinue long-term NA therapy. During this study participants will cease their prescribed medications, this will occur with immediate effect once enrolled into the study. The duration of cessation will be indefinite, unless clinically indicated for NA therapy re-start. Participants will be monitored as per protocol following cessation, monitoring will be by clinic visit and through blood test to monitor virological response. Clinical visits will be at the intervals of week 2, week, 4, week 8, week 12, week 18, following this they will be every 3 months out to 2 years when the participant will have completed the trial. Once the participant has completed the trial they will not commence again, the aim is for an indefinite cessation of NA therapy.

NCT ID: NCT02532413 Recruiting - Chronic Hepatitis B Clinical Trials

Antiviral Efficacy of the Combination Treatment With Poly IC and Entecavir for Chronic Hepatitis B

Start date: July 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate antiviral efficacy of the combination treatment with Poly IC and Entecavir and compare with the efficacy of Entecavir mono-therapy for chronic hepatitis B.

NCT ID: NCT02523547 Recruiting - Chronic Hepatitis B Clinical Trials

Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude

Start date: January 2015
Phase: Phase 4
Study type: Interventional

Open-labeled, Prospective, Randomized, Multi-center, Interventional, Phase IV study.